EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Anti-Microbial Savior BioteQ Co., Ltd. (6864) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Anti-Microbial Savior BioteQ Co., Ltd. TWD 10.42, price TWD 50.30, upside -79.3%, quality 25 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · TW · ISIN TW0006864002

AM Thin data Sep 24, 2026

Anti-Microbial Savior BioteQ Co., Ltd.

6864 · TWO

Weakest SetupStrongly overvalued and low quality.

!Fair value 10.42 TWD · Strongly overvalued (−79%)
!Quality 25/100
!Weak Growth (revenue 3y −36.0 %/yr)
!Low debt · negative free cash flow
!Trails peers (3/8)
!Narrow moat 3/100
!Insider activity 45/100
!Evidence only low, so the estimate is less certain
Watch Anti-Microbial Savior BioteQ Co., Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

86.30 TWD 40.00 TWD Fair Value 10.42 TWD Dec 2025 Sep 2026

White line = price, green steps = our fair value per fiscal year. As of Sep 24, 2026.

How to read this chart

10‑month range 40.00 TWD – 86.30 TWD · fair‑value band 6.88 TWD – 13.03 TWD · the 50.30 TWD price screens above the 10.42 TWD fair value. As of Sep 24, 2026.

Follow Anti-Microbial Savior BioteQ Co. in your weekly email

Every Wednesday you see whether Anti-Microbial Savior BioteQ Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Anti-Microbial Savior BioteQ Co., Ltd. focuses on the research and development of pharmaceutical drug products in Taiwan. It develops technology patenting of medical fungi. The company also provides MEDIACE, an antibacterial Ingredient containing skin-friendly materials and medicinal fungal extracts.

Show more

Anti-Microbial Savior BioteQ Co., Ltd. focuses on the research and development of pharmaceutical drug products in Taiwan. It develops technology patenting of medical fungi. The company also provides MEDIACE, an antibacterial Ingredient containing skin-friendly materials and medicinal fungal extracts. In addition, it provides customized functional face masks. The company was founded in 2018 and is headquartered in Kaohsiung, Taiwan.

Stock analysis

Anti-Microbial Savior BioteQ Co., Ltd. (6864) currently trades at 50.30 TWD, while our model-based Fair Value estimate is 10.42 TWD, implying the stock looks roughly 382.6% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 6.88 TWD (bear) to 13.03 TWD (bull), the price of 50.30 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Anti-Microbial Savior BioteQ Co., Ltd. reported revenue of 706K TWD in FY2025 versus 88.0K TWD in FY2021, a compound +68.3%/yr. Reported net income was −93.6M TWD in FY2025.

Key figures

Market cap 1.9B TWD (≈ $59.6M) · EPS (TTM) −2.58 TWD · Return on equity −25.0% · Return on assets (EBIT) −26.5% · Operating margin −16,567% · Revenue (TTM) 706K TWD · Revenue growth (YoY) +38.3% · Free cash flow −84.6M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).

What moves the price

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −79%, 6864 screens richer than that median.

Fair Value models

Bear 6.88 TWD Fair Value 10.42 TWD Bull 13.03 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 6.74 TWD 9.03 TWD 13.48 TWD 54
All 1 models by family
Asset-Based
NCAV (Graham) 6.74 TWD 9.03 TWD 13.48 TWD 54

Open the full fair value analysis →

Notify me when 6864 reaches fair value

Put 6864 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 25/100

Of which business quality 33 · Market factors (momentum, volatility) 35

Profitability 0
Margins and returns on capital today
Quality Growth 79
Are margins and returns improving?
Cashflow 7
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 40
Price trend over the last 3–12 months (market factor)
52W Momentum 11
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+15.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−36.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−32,164.8% (2021) → −13,595.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6864 screens 383% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Anti-Microbial Savior BioteQ Co., Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 649 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 33 · Bottom 25%
Fair Value upside −79% · Bottom 25%
Profitability
Return on assets −16% · Below median
Growth and dividend
Revenue growth 38% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.12× · Cheapest 25%
P/S (TTM) 84.91× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 23

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $516.34 $567.97 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Anti-Microbial Savior BioteQ Co., Ltd. · Fair Value
10.42 TWD −383%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Anti-Microbial Savior BioteQ Co., Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/6864

Frequently asked questions

Is Anti-Microbial Savior BioteQ Co., Ltd. (6864) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 10.42 TWD versus a price of 50.30 TWD, about −79% upside (overvalued).
What is the fair value of 6864?
Our model-based fair value for Anti-Microbial Savior BioteQ Co., Ltd. is 10.42 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 50.30 TWD.
What is the quality score of 6864?
Anti-Microbial Savior BioteQ Co., Ltd. has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Anti-Microbial Savior BioteQ Co., Ltd. (6864)?
Our model-based price target is the fair value of 10.42 TWD (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 6.88 TWD, optimistic scenario 13.03 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Anti-Microbial Savior BioteQ Co., Ltd. stock forecast for 2026?
Our models put fair value at 10.42 TWD, about −79% upside versus a price of 50.30 TWD (overvalued). Cautious scenario 6.88 TWD, optimistic scenario 13.03 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Anti-Microbial Savior BioteQ Co., Ltd. (6864)?
Anti-Microbial Savior BioteQ Co., Ltd. reported trailing-twelve-month revenue of about 706K TWD (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Anti-Microbial Savior BioteQ Co., Ltd. (6864)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Anti-Microbial Savior BioteQ Co., Ltd. it is 10.42 TWD per share (as of Sep 24, 2026), against a price of 50.30 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Anti-Microbial Savior BioteQ Co., Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6864 trades above its calculated fair value: price 50.30 TWD, fair value 10.42 TWD, a gap of about −79% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6864?
No. The price is what the market pays today (50.30 TWD); the fair value is what the company's own numbers justify (10.42 TWD). For Anti-Microbial Savior BioteQ Co., Ltd. the two are 39.88 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Anti-Microbial Savior BioteQ Co., Ltd. worth?
The market values Anti-Microbial Savior BioteQ Co., Ltd. at about 1.9B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 50.30 TWD; our models calculate a fair value of 10.42 TWD per share.
What do the bullish and bearish scenarios say about 6864?
Our models span a range for Anti-Microbial Savior BioteQ Co., Ltd.: cautious scenario 6.88 TWD, base 10.42 TWD, optimistic 13.03 TWD per share (as of Sep 24, 2026, price 50.30 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Anti-Microbial Savior BioteQ Co., Ltd. (6864)?
Balance-sheet figures for Anti-Microbial Savior BioteQ Co., Ltd. (as of Sep 24, 2026): return on equity −25.0%. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
Which stocks are comparable to Anti-Microbial Savior BioteQ Co., Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Anti-Microbial Savior BioteQ Co., Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price 50.30 TWD, calculated fair value 10.42 TWD (−79%), Quality Score 25/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6864 calculated?
We run Anti-Microbial Savior BioteQ Co., Ltd. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 10.42 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Anti-Microbial Savior BioteQ Co., Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Anti-Microbial Savior BioteQ Co., Ltd. (6864)?
The closing price on Sep 24, 2026 was 50.30 TWD. Our model-based fair value is 10.42 TWD, about −79% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Anti-Microbial Savior BioteQ Co., Ltd. right now?
The price sits above even our optimistic bull case (13.03 TWD). The favourable scenario is already priced in. Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (6.88 TWD to 13.03 TWD) leaves room in how you read the outcome.

Key figures of Anti-Microbial Savior BioteQ Co., Ltd.

How large is the market capitalisation of Anti-Microbial Savior BioteQ Co., Ltd. (6864)?
The market capitalisation of Anti-Microbial Savior BioteQ Co., Ltd. is 1.9B TWD (≈ $59.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Anti-Microbial Savior BioteQ Co., Ltd. (6864)?
Earnings per share at Anti-Microbial Savior BioteQ Co., Ltd. are −2.58 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Anti-Microbial Savior BioteQ Co., Ltd. (6864)?
The return on equity (ROE) of Anti-Microbial Savior BioteQ Co., Ltd. is −25.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Anti-Microbial Savior BioteQ Co., Ltd. (6864)?
On an EBIT basis the return on assets of Anti-Microbial Savior BioteQ Co., Ltd. is −26.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Anti-Microbial Savior BioteQ Co., Ltd. (6864)?
The operating margin of Anti-Microbial Savior BioteQ Co., Ltd. is −16,567% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Anti-Microbial Savior BioteQ Co., Ltd. (6864)?
Revenue at Anti-Microbial Savior BioteQ Co., Ltd. is growing +38.3% versus a year earlier (3y avg −36.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Anti-Microbial Savior BioteQ Co., Ltd. (6864) generate?
The free cash flow of Anti-Microbial Savior BioteQ Co., Ltd. is −84.6M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Anti-Microbial Savior BioteQ Co., Ltd. in the live analysis

One click puts Anti-Microbial Savior BioteQ Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.